Sort   by:  
 Page size 

The ultimate goal of surgical treatment in cancer is to remove the tumor mass for restoring a healthy state. A 16-lipid panel that discriminated healthy controls from clear cell renal cell carcinoma (ccRCC) patients in a prior study was evaluated in the present work in paired-serum samples collec...

2023-01-02 | MTBLS3838 | MetaboLights
Renal tumors that arise in individuals with BHD Syndrome represent a molecularly distinct form of renal cancer. In addition, BHD syndrome is due to a mutation the folliculin gene (FLCN). While the folliculin gene is an important tumor suppressor gene, the molecular function of this gene is not well...
ORGANISM(S): Homo sapiens 

Metabolic reprogramming is critical for tumor initiation and progression. However, the exact impact of specific metabolic changes on cancer progression is poorly understood. Here, we integrate multimodal analyses of primary and metastatic clonally-related clear cell renal cancer cells (ccRCC) gro...

2022-12-08 | MTBLS5615 | MetaboLights
A protocol for harvesting and extracting extracellular metabolites from an in vitro model of human renal cell lines was developed to profile the exometabolome by means of a discovery-based metabolomics approach using ultraperformance liquid chromatography coupled to quadrupole-time-of-flight mass sp...
2018-11-14 | MTBLS737 | MetaboLights

Clear cell renal cell carcinoma (ccRCC) is the most common kidney malignancy. Yet, no rapid, non-invasive biomarkers are available for diagnosis or screening. Urine represents an ideal analyte matrix due to its accessibility, low invasiveness, longitudinal sampling and the kidney’s central role i...

2026-08-16 | MTBLS12025 | MetaboLights

Germline or somatic loss-of-function of fumarate hydratase (FH) predisposes patients to an aggressive form of renal cell carcinoma (RCC). Since other than tumor resection, there is no effective therapy for FH-deficient RCC, a competent method for early diagnosis and for early detection of recurre...

2022-08-12 | MTBLS3628 | MetaboLights

Clear cell renal cell carcinoma (ccRCC) is a kidney malignancy characterized by aberrant lipid accumulation and is intrinsically sensitive to ferroptosis. However, the mechanisms by which ccRCC escapes ferroptotic vulnerability remain poorly understood. Here, we report that fumarate hydratase (FH...

2026-10-16 | MTBLS15364 | MetaboLights

Clear cell renal cell carcinoma (ccRCC) is the most common kidney malignancy. Yet, no rapid, non-invasive biomarkers are available for diagnosis or screening. Urine represents an ideal analyte matrix due to its accessibility, low invasiveness, longitudinal sampling and the kidney’s central role i...

2026-07-15 | MTBLS14671 | MetaboLights

Metabolic reprogramming is a defining feature of cancer; however, how it contributes to therapeutic resistance remains incompletely understood. Here we show that loss of aldo-ketoreductase 1A1 (AKR1A1) in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) disrupts terminal glycolytic f...

2026-07-10 | MTBLS15003 | MetaboLights
Clear cell renal cell carcinoma (ccRCC) is pathologically characterized by profound intracellular lipid droplet accumulation. To explore the dysregulated lipid metabolic network and identify crucial drivers, an integrated transcriptomic and untargeted metabolomic analysis was conducted. In this stud...
2026-08-31 | MTBLS15414 | MetaboLights
Sort   by:  
 Page size